Navigation Links
Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex (Ferric Citrate) for the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients
Date:6/8/2009

fective and safe treatment in lowering and/or maintaining normal serum phosphorus levels in patients with ESRD and hyperphosphatemia.

Sales of phosphate binders to treat hyperphosphatemia in ESRD patients in the U.S. were approximately $600 million in 2007, and has grown in excess of 20% per annum over the last five years.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Keryx is developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex has recently completed a Phase 2 clinical program as a treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease. The Company is also developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that modulates Akt, a protein in the body associated with tumor survival and growth. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types. The Company also actively engages in business development activities that include seeking strategic relationships for its product candidates and for the Company, as well as evaluating compounds and companies for in-licensing or acquisition. Keryx is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release, particularly those anticipating future clinical and business prospects for Zerenex and KRX-0401, may be forward-looking statements th
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
2. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
3. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
4. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
6. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
7. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
8. Keryx Biopharmaceuticals Announces Additions to Management Team
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
10. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
11. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 10, 2014 /PRNewswire-iReach/ -- Tute Genomics, the ... announced an agreement with Lineagen, Inc., to ... NextStep Dx PLUS.  Lineagen, focused on ... disorders, currently offers FirstStep Dx PLUS, ... used by healthcare providers as a first-line ...
(Date:7/10/2014)... April 15, 2014 -- According to the International ... nuclear security comes from terrorists acquiring sufficient quantities ... construct a crude nuclear explosive device. The IAEA ... trafficking have involved gram-level quantities, which can be ... According to a new study appearing this week ...
(Date:7/10/2014)... in the journal PNAS (Proceedings of the National ... day and sleep deprivation have a significant effect on ... at the best time of day to test for ... administering medicines effectively. , Researchers from the University of ... the links between sleep deprivation, body clock disruption and ...
(Date:7/10/2014)... The lithium-ion batteries that power our laptops and ... on a single charge with the help of a ... material to replace the graphite traditionally used in one ... 10 times the energy storage capacity of graphite. A ... electrode was published today in Nature Communications . ...
Breaking Biology Technology:Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4Sensitive detection method may help impede illicit nuclear trafficking 2Time of day crucial to accurately test for diseases, new research finds 2Silicon sponge improves lithium-ion battery performance 2Silicon sponge improves lithium-ion battery performance 3
... weeks back, we took a look at the results of the ... that time, we saw that the Midwest had two states in the ... the top 20 states. I promised to circle back with you to ... the Midwest fared in this ranking. , ,The NIH falls under ...
... slowly getting over its shyness about asking for federal ... business executives is learning more about how ... Business Technology Transfer Conference at the Hilton Milwaukee ... programs, one (SBIR) designed to foster small business innovation, ...
... - Angel and venture investors have fewer secrets ... dispense some advice to early-stage executives during the National ... with scientific ties to the University of Wisconsin-Madison ... their products have a sustainable market advantage, and what ...
Cached Biology Technology:Midwest colleges strong contenders for NIH funds 2Midwest colleges strong contenders for NIH funds 3Midwest colleges strong contenders for NIH funds 4Midwest colleges strong contenders for NIH funds 5Wisconsin firms urged to pursue federal SBIR dollars 2Wisconsin firms urged to pursue federal SBIR dollars 3Early-stage executives hear from investors 2Early-stage executives hear from investors 3
(Date:7/11/2014)... mesenchymal stem cells can stimulate neurogenesis in the brain ... (AD) and improve tissue and function injury under the ... the therapeutic effect of adipose-derived stem cells (ADSCs) transplantation ... oxidative injury and neurogenesis in the brain of AD ... Life Sciences, Tsinghua University, China transplanted ADSCs into the ...
(Date:7/11/2014)... toxins to study the proteins that let nerve cells ... have stumbled upon a biological tactic that may offer ... in a safe and environmentally responsible way. , ... for one species and harmless for a closely related ... pests without harming beneficial species like bees. A summary ...
(Date:7/10/2014)... BEDFORD, Mass. , June 30, 2014  Aware, ... of biometrics software and services, previously announced on June ... a special cash dividend of $1.75 per share, or ... record date of July 10, 2014 and a payment ... notified by NASDAQ that it had set an ex-dividend ...
Breaking Biology News(10 mins):Potent spider toxin 'electrocutes' German, not American, cockroaches 2Potent spider toxin 'electrocutes' German, not American, cockroaches 3NASDAQ Sets Ex-Dividend Date for Aware, Inc.'s Special Cash Dividend of $1.75 Per Share 2
... This release is available in French . ... the Minister of Industry, on behalf of the Honourable ... the Natural Sciences and Engineering Research Council of Canada ... announced that Nobel Laureate John C. Polanyi is the ...
... have a sizeable biofuels industry based primarily on local ... and new conversion technologies are used, according to a ... Northwest National Laboratory. It will be difficult ... based on todays land use practices with currently available ...
... WINSTON-SALEM, N.C. A small group of patients with ... veins with an injectable microfoam experienced no neurological, visual ... according to preliminary results from a phase II trial. ... Washington, D.C., at the annual scientific meeting of the ...
Cached Biology News:Dr. John Polanyi wins Canada's most prestigious science award 2Key to using local resources for biomass may include waste 2Key to using local resources for biomass may include waste 3Improved foam for varicose veins found to be safe in preliminary results from phase II trial 2
Dual-bay Dyad thermal cycler chassis, does not include the Alpha units (requires 2)...
... dual-bay DNA Engine Dyad thermal cycler ... amplification (PCR). The chassis accommodates a ... heat-pump assemblies), which hold different types ... offers graphical programming with point-and-click navigation. ...
... Red fluorescent RNA stain is used to ... or glyoxal) agarose gels and does not ... a 302 nm transilluminator, the stain emits ... on Polaroid film or with a CCD ...
... The MitoPT kit is used in conjunction ... in culture and induce apoptosis according to your ... cells as a negative control). Once you have ... MitoPT solution to each population and incubate the ...
Biology Products: